Project Grant R01HL181357
Award Date 7/7/26
Completion Date 3/31/28
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Roxbury, MA 02118, USA
Similar Awards
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $490,500 Project Grant to Boston University Medical Campus (Trustees of Boston University) beginning September 1, 2025, with a completion date of May 31, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). The research investigates novel mechanistic insights into inflammation and organ injury resulting from dysregulated host defense in bacterial pneumonia and sepsis....
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston University Medical Campus a $1.58 million Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) effective July 9, 2026, through March 31, 2028, to conduct basic research investigating the protective role of G-protein subunit beta 2 (GNB2) in macrophages during Legionella pneumophila infection. The project delivers fundamental biomedical research services focused on understanding host...
- Federal Project Grant Award Summary Boston University Medical Campus received a $122,625 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) beginning June 1, 2025 and concluding May 31, 2027. The award funds research and development of novel small molecule therapeutics targeting oxidized sirtuin-1 (SIRT1) as a potential treatment for aortic aneurysms in Marfan Syndrome. The research deliverables...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Feinstein Institutes for Medical Research a Project Grant of $586,866 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 15, 2026, with a completion date of February 28, 2030. This award funds research investigating the critical role of B-1A cells, an immunoregulatory B cell subset, in mitigating acute lung injury (ALI) and acute respiratory distress...
- Federal Project Grant Award Summary Boston University Medical Campus received a $150,342 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 30, 2026, with completion targeted for June 30, 2029. The award funds research investigating the mechanisms of a conserved niche endothelial program that directs hematopoietic stem cell (HSPC) migration into bone marrow during stem cell...
- Federal Grant Award Summary Saint Louis University received a $617,477 Project Grant award from the National Heart, Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 16, 2026, with completion scheduled for April 30, 2030. The award funds research to identify mechanisms of plasmalogen dysregulation during sepsis and develop therapeutic interventions targeting this condition. The project investigates how oxidative stress during sepsis...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,380,481 Project Grant to the University of Pittsburgh under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic and translational research on indole metabolites as xenobiotic danger signals in acute lung injury. The award, effective September 1, 2025, through May 31, 2029, supports a research program led by a pulmonary and critical care physician investigating the intersection...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) awarded Massachusetts General Hospital a Project Grant of $1,579,554 on September 10, 2025, for research concluding June 30, 2030. The award funds an integrated genomic and functional research initiative to decipher the mechanisms underlying chronic obstructive pulmonary disease (COPD) and asthma—two of the most common and costly chronic respiratory...
- Federal Project Grant Award Summary Brigham and Women's Hospital received a $1,540,621 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for June 30, 2030. The award funds basic science research into the molecular mechanisms driving early-stage pulmonary arterial hypertension (PAH), with particular focus on endothelial inflammation, C-terminal SRC kinase...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received a $1.41 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for May 31, 2029. The award funds research to characterize lung interstitial neutrophils (LINs)—a specialized immune cell subset with enhanced bactericidal capacity. The project investigates the origin,...